ArticleCancer biology & therapy2019
The
Article in Cancer biology & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Rare exon 18 G719A and exon 21 L833V compound EGFR mutations show favorable response to Third-Generation TKI Furmonertinib: A case report and literature review.Investigational new drugs · 2025Review
- Inherited rare epidermal growth factor receptor mutation and somatic mutations in patients with non-small cell lung cancer: a case report.BMC medical genomics · 2025Article
- Treatment of advanced lung adenocarcinoma with EGFR L833V/H835L compound mutations using furmonertinib: two case reports and literature review.Frontiers in medicine · 2025Article
- Article
- Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors.Nature cancer · 2024Article
- An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report.Journal of medical case reports · 2024Article
- [A Rare Case of Lung Adenocarcinoma with EGFR L833V/H835L Co-mutation and Literature Review].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Review
- Successful treatment of lung adenocarcinoma complicated with a rare compoundFrontiers in pharmacology · 2023Article
- Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib.Lung Cancer (Auckland, N.Z.) · 2023Article
- Case report: sequential use of almonertinib based on theTranslational cancer research · 2022Article
- Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report.World journal of clinical cases · 2021Article
- The therapeutic potential of attenuated diphtheria toxin delivered by an adenovirus vector with survivin promoter on human lung cancer cells.Cancer biology & therapy · 2021Article
- The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report.Annals of translational medicine · 2021Article
- The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.Cancer medicine · 2020Article
- Next Generation Sequencing Reveals a Synchronous Trilateral Lung Adenocarcinoma Case with Distinct Driver Alterations of EGFR 19 Deletion or EGFR 20 Insertion or EZR-ROS1 Fusion.OncoTargets and therapy · 2020Article
- Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report.OncoTargets and therapy · 2020Article
- Clinical Response to Osimertinib in a Non-Small-Cell Lung Cancer Patient With EGFR L833V/H835L Mutations: A Case Report.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Literatures regarding the prevalence and clinical significance of compound EGFR mutations are limited. Until now, none of retrospective or prospective research has focused on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.